Search results for " MAntle"

Aluminium distribution in an Earth's non–primitive lower mantle

2020

The aluminium incorporation mechanism of perovskite was explored by means of quantum mechanics in combination with equilibrium/off-equilibrium thermodynamics under the pressure-temperature conditions of the Earth's lower mantle (from 24 to 80 GPa). Earth's lower mantle was modelled as a geochemically non-primitive object because of an enrichment by 3 wt% of recycled crustal material (MORB component). The compositional modelling takes into account both chondrite and pyrolite reference models. The capacity of perovskite to host Al was modelled through an Al2O3 exchange process in an unconstrained Mg-perovskite + Mg-Al-perovskite + free-Al2O3(corundum) system. Aluminium is globally incorporate…

Noble gas and CO2 isotopic signatures of the lithospheric mantle underneath Mexico and the Canary Islands: clues from mantle xenoliths and arc lavas

2022

Studying the isotopic composition of fluids trapped in mantle xenoliths opens avenues to understand the origin and cycling of volatiles in the Earth’s upper mantle. In this PhD dissertation, new and in most cases the very first data regarding the isotopic (noble gases and CO2) characterization of the lithospheric mantle portions of three different geodynamic environments are presented: (i) Central and NW Mexico, a continental setting dominated by extension; (ii) the Transmexican Volcanic Belt (TMVB) a subduction setting, and (iii) the Canary Islands, particularly El Hierro and Lanzarote, two oceanic islands formed by mantle plume-derived intraplate volcanism. In total 32 peridotites (includ…

Evidence of Two-Component Iblean-Like Mantle From 2001-2006 Igneous Products of Mount Etna

2008

EVIDENCES OF ENRICHED MANTLE (EM-2) SOURCE CONTRIBUTION TO ETNEAN MAGMAS: A COMPREHENSIVE STUDY ON FLUID AND MELT INCLUSIONS OF 2001-2006 ERUPTIONS

2009

Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mant…

2017

Mantle cell lymphoma (MCL) is a rare, aggressive, incurable B-cell malignancy. Ibrutinib has been shown to be highly active for patients with relapsed/refractory (R/R) MCL. The RAY trial (MCL3001) was a phase 3, randomized, open-label, multicenter study that compared ibrutinib with temsirolimus in patients with R/R MCL. Active disease is frequently associated with impaired functional status and reduced well-being. Therefore, the current study employed two patient-reported outcome instruments, the Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym) and the EQ-5D-5L, to assess symptoms, well-being, health status, and health-related quality of life of patients on treatment within the R…

Treatment for patients with relapsed/refractory mantle cell lymphoma: European-based recommendations

2017

International audience; Patients with mantle cell lymphoma (MCL) usually respond to initial combination chemotherapy, but the disease inevitably relapses and often follows an aggressive course. Here, clinical study results published since 2008 for patients with relapsed/refractory MCL were reviewed to compare available evidence for treatment guidance. Most trials identified were non-randomized, phase II studies performed at a limited number of sites, and many evaluated MCL as one of multiple non-Hodgkin lymphoma subtypes. Additional randomized, comparative trials are needed. Treatment selection generally depends on patient need, age and fitness, time of relapse, and line of therapy. Combina…

Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies

2017

Ibrutinib is highly active in treating mantle cell lymphoma (MCL), an aggressive B-cell lymphoma. We pooled data from three ibrutinib studies to explore the impact of baseline patient characteristics on treatment response. Patients with relapsed/refractory MCL (n = 370) treated with ibrutinib had an objective response rate (ORR) of 66% (20% complete response; 46% partial response); median duration of response (DOR), progression-free survival (PFS) and overall survival (OS) were 18.6, 12.8 and 25.0 months, respectively. Univariate analyses showed patients with one versus >one prior line of therapy had longer OS. Multivariate analyses identified that one prior line of therapy affected PFS; Ea…

Temsirolimus in mantle cell lymphoma and other non-Hodgkin lymphoma subtypes.

2009

Temsirolimus, an inhibitor of mammalian target of rapamycin (mTOR), has anti-tumor activity in patients with relapsed or refractory mantle cell lymphoma (MCL) and other mature lymphoid neoplasms. mTOR is an intracellular kinase that controls the mRNA translation of many proteins (eg, cyclin D1) that can act as oncogenes and contribute to lymphomagenesis. Characterized by overexpression of cyclin D1, MCL was identified as a disease that might be susceptible to mTOR inhibition. When single-agent temsirolimus was explored in two phase II studies for treatment of patients with relapsed or refractory MCL, it demonstrated anti-tumor activity, with overall response rates of 38% and 41%. Subsequent…

Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis

2019

Relapsed and/or Refractory Mantle Cell Lymphoma: What Role for Temsirolimus?

2012

Mantle Cell Lymphoma (MCL) is associated with a dismal prognosis. Recently, along with the improved understanding of the pathophysiology of this disease, new first line regimens have been established and in addition novel treatment options have entered the clinical arena. In consequence, prognosis of the disease has fortunately improved. We here focus on the rationale, current clinical knowledge and future concepts of Temsirolimus, an inhibitor of mTOR, in the treatment of MCL. At this time this drug has been shown to be effective as single agent for relapsed disease and early combination data show promising results. In addition, with a brief outline of other treatment options, we aim to g…